Stock Analiz

CorMedix Inc. (CRMD) stock forecast and price target

Price $4.66 · data as of November 13, 2026

12-month price target

Average target$13.80
Upside / downside+196.1%
Analysts5
ConsensusBuy
Low $12.00Average $13.80High $17.00

Gold marker: average target · white marker: today’s price ($4.66)

Analyst ratings

Strong buy 3Buy 2Hold 0Sell 0Strong sell 0

Earnings and revenue estimates

PeriodEPS estimateEPS growthRevenue estimate
Current fiscal year
ends December 31, 2026
$0.43—$335M
Next fiscal year
ends December 31, 2027
$-0.06—$316M
Next quarter
ends December 31, 2026
$-0.16—$52M
Quarter after
ends March 31, 2027
$-0.06—$68M

Consensus of the analysts covering CorMedix, updated daily. In the last 30 days 2 estimates were raised and 3 lowered.

Our model vs. Wall Street

Analysts see 196.1% upside over 12 months. Our discounted cash flow model with moderate assumptions puts CorMedix’s intrinsic value about 65% below today’s market value, and it scores 3.0 out of 5 on our checks. Price targets follow sentiment; a DCF follows cash. When both point the same way the signal is stronger. Try your own assumptions.

Frequently asked questions

What is the CorMedix stock price target?

The average 12-month target from 5 analysts is $13.80, 196.1% above the current price of $4.66 Targets range from $12.00 to $17.00.

Is CorMedix a buy according to analysts?

The consensus rating is “Buy” (3 strong buy, 2 buy). Ratings are opinions, not guarantees; this is not investment advice.

How much is CorMedix expected to earn?

Analysts expect EPS of $0.43 for the fiscal year ending December 31, 2026 and $-0.06 the year after.

Analyst consensus estimates and price targets, updated daily. Forecasts can be wrong; this is information, not investment advice.